779 related articles for article (PubMed ID: 34959021)
1. Evaluation of effect of empirical attack-preventive immunotherapies in neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis.
Ma J; Yu H; Wang H; Zhang X; Feng K
J Neuroimmunol; 2022 Feb; 363():577790. PubMed ID: 34959021
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis.
Wang Y; Ma J; Chang H; Zhang X; Yin L
Mult Scler Relat Disord; 2021 Oct; 55():103181. PubMed ID: 34365314
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of rituximab in the treatment of neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis.
Wang Y; Chang H; Zhang X; Yin L
Mult Scler Relat Disord; 2021 May; 50():102843. PubMed ID: 33609924
[TBL] [Abstract][Full Text] [Related]
4. Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder.
Yang Y; Wang CJ; Wang BJ; Zeng ZL; Guo SG
J Neurol Sci; 2018 Feb; 385():192-197. PubMed ID: 29406904
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of azathioprine, mycophenolate mofetil, and rituximab in the treatment of neuromyelitis optica spectrum disorder and analysis of prognostic factors.
Zhang L; Tian J; Dong X; Jia Z; Sun Y; Guo L; Tan G; Li B
Neurol Sci; 2022 Apr; 43(4):2651-2658. PubMed ID: 34585292
[TBL] [Abstract][Full Text] [Related]
6. Comparisons of the efficacy and tolerability of mycophenolate mofetil and azathioprine as treatments for neuromyelitis optica and neuromyelitis optica spectrum disorder.
Chen H; Qiu W; Zhang Q; Wang J; Shi Z; Liu J; Lian Z; Feng H; Miao X; Zhou H
Eur J Neurol; 2017 Jan; 24(1):219-226. PubMed ID: 27783452
[TBL] [Abstract][Full Text] [Related]
7. Effective Rituximab Treatment in Patients with Neuromyelitis Optica Spectrum Disorders Compared with Azathioprine and Mycophenolate.
Yang Y; Chen L; Wu L; Yao J; Wang N; Su X; Li D; Han L; Wu W; Huang D; Jiang T; Wang Z
Neurol Ther; 2022 Mar; 11(1):137-149. PubMed ID: 34797551
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of azathioprine, mycophenolate mofetil, and reduced dose of rituximab in neuromyelitis optica spectrum disorder.
Huang W; Wang L; Xia J; Li W; Wang M; Yu J; Li Q; Wang B; Pan J; Du L; Ma J; Tan H; Chang X; Lu C; Zhao C; Lu J; Zhou L; ZhangBao J; Quan C;
Eur J Neurol; 2022 Aug; 29(8):2343-2354. PubMed ID: 35398950
[TBL] [Abstract][Full Text] [Related]
9. Different monoclonal antibodies and immunosuppressants administration in patients with neuromyelitis optica spectrum disorder: a Bayesian network meta-analysis.
Yin Z; Qiu Y; Duan A; Fang T; Chen Z; Wu J; Wang Z; Chen G
J Neurol; 2023 Jun; 270(6):2950-2963. PubMed ID: 36884069
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of modified reduced-dose rituximab in Chinese patients with neuromyelitis optica spectrum disorder: A retrospective cohort study.
Cao S; Yu H; Tian J; Li Y; Shen Y; Ji X; Wang X; Zhou X; Gu Y; Zhu F; Duan X; Xiao X; Fang Q; Chen X; Xue Q
J Neurol Sci; 2021 Oct; 429():117616. PubMed ID: 34450520
[TBL] [Abstract][Full Text] [Related]
11. A meta-analysis comparing first-line immunosuppressants in neuromyelitis optica.
Giovannelli J; Ciron J; Cohen M; Kim HJ; Kim SH; Stellmann JP; Kleiter I; McCreary M; Greenberg BM; Deschamps R; Audoin B; Maillart E; Papeix C; Collongues N; Bourre B; Laplaud D; Ayrignac X; Durand-Dubief F; Ruet A; Vukusic S; Marignier R; Dauchet L; Zephir H;
Ann Clin Transl Neurol; 2021 Oct; 8(10):2025-2037. PubMed ID: 34505407
[TBL] [Abstract][Full Text] [Related]
12. Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and cyclophosphamide among patients with neuromyelitis optica spectrum disorder: A prospective cohort study.
Xu Y; Wang Q; Ren HT; Qiao L; Zhang Y; Fei YY; Zhao Y; Cui LY
J Neurol Sci; 2016 Nov; 370():224-228. PubMed ID: 27772764
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of azathioprine for neuromyelitis optica spectrum disorder: A systematic review and meta-analysis.
Espiritu AI; Pasco PMD
Mult Scler Relat Disord; 2019 Aug; 33():22-32. PubMed ID: 31136907
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of efficacy and tolerability of first-line therapies in NMOSD.
Poupart J; Giovannelli J; Deschamps R; Audoin B; Ciron J; Maillart E; Papeix C; Collongues N; Bourre B; Cohen M; Wiertlewski S; Outteryck O; Laplaud D; Vukusic S; Marignier R; Zephir H;
Neurology; 2020 Apr; 94(15):e1645-e1656. PubMed ID: 32170036
[TBL] [Abstract][Full Text] [Related]
15. Meta-analysis of the effectiveness of relapse prevention therapy for myelin-oligodendrocyte glycoprotein antibody-associated disease.
Chang X; Zhang J; Li S; Wu P; Wang R; Zhang C; Wu Y
Mult Scler Relat Disord; 2023 Apr; 72():104571. PubMed ID: 36905816
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of rituximab versus oral immunosuppressive therapies in neuromyelitis optica spectrum disorder in a racially diverse cohort of subjects: A single-center retrospective study.
Dresser L; Chaar WA; Reder AT; Abuaf AF; Cipriani VP; Javed A
Mult Scler Relat Disord; 2023 Jun; 74():104718. PubMed ID: 37086634
[TBL] [Abstract][Full Text] [Related]
17. Comparative Analysis of Treatment Outcomes in Patients with Neuromyelitis Optica Spectrum Disorder Treated with Rituximab, Azathioprine, and Mycophenolate Mofetil: A Systematic Review and Meta-analysis.
Magdalena C; Clarissa A; Sutandi N
Innov Clin Neurosci; 2022; 19(4-6):51-64. PubMed ID: 35958974
[TBL] [Abstract][Full Text] [Related]
18. Meta-analysis of effectiveness of steroid-sparing attack prevention in MOG-IgG-associated disorder.
Thakolwiboon S; Zhao-Fleming H; Karukote A; Mao-Draayer Y; Flanagan EP; Avila M
Mult Scler Relat Disord; 2021 Nov; 56():103310. PubMed ID: 34634625
[TBL] [Abstract][Full Text] [Related]
19. A comparison of the efficacy of tocilizumab versus azathioprine for neuromyelitis optica spectrum disorder: A study protocol for systematic review and meta-analysis.
Tang Q; Yao M; Huang Y; Bian J; Wang Y; Ji W
Medicine (Baltimore); 2023 Jan; 102(4):e32748. PubMed ID: 36705346
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Long-Term Use of Low Dose Rituximab and Mycophenolate Mofetil in Chinese Patients With Neuromyelitis Optica Spectrum Disorder.
Lin J; Xue B; Li J; Zhu R; Pan J; Chen Z; Zhang X; Li X; Xia J
Front Neurol; 2022; 13():891064. PubMed ID: 35599732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
